remember cramer fav regeneron was better than everybody else and based on early trials looks like the last even longer. avalanche became public in july of last year at $17. back in january the company did a 2.5 million share secondary. then the stock got hammered at 33. a matter of weeks. since then they rebounded without much news from the company. it could be a promising speculative story long time. i still like regeneron but i can't endorse this stock all the way up here. the stock has recently gone into the companies a analyst day this wednesday. the time to buy avalanche was $10 after it got pancaked by the secondary offering. finally last thursday mark in tennessee called in about northwest bio therapeutics. that's a tiny $500 million bio tech. up 41% year to date. it's a development staged bio tech with a platform where they used activated cells to mobilize a patient's own immune system to attack many differ type of cancer. it actually became public in 2001 and collapsed shortly there after. lately the stock has been roaring because they got approval from health canada. a phase